Abstract: The present invention relates to a method for the treatment of myocardial infarction. In particular the invention relates to the treatment of myocardial infarction using inhibitors of a particular enzyme involved in glucocorticoid metabolism.

Abstract: Animal stem cells are obtained and maintained by culturing cells containing, in the genome, a selectable marker. Differential expression of the selectable marker enables preferential survival and/or division of the desired stem cells compared to the non-stem cells.

Abstract: A vehicle guidance system comprising: a measurement system; a processor arranged to receive information from the measurement system and convert said information into at least one time-to-contact based parameter; and a control system arranged to receive the at least one time-to-contact based parameter from the processor and use the at least one time-to-contact based parameter to either automatically guide the vehicle or to provide vehicle guidance information to a pilot.

Abstract: Pluripotent cells are maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and, optionally, an antagonist of an FGF receptor. Pluripotent cells are also maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor and an antagonist of an FGF receptor.

Abstract: A method for generating a culture that is purified or enriched in respect of cells of a selected lineage is described in which a selectable marker, which is differentially expressed in cells of the selected lineage compared with its expression in other cells, is introduced into a multipotential cell and the multipotential cell is cultured to induce differentiation of the multipotential cell into a cell of the selected lineage or into a mixture of cells including cells of the selected lineage, or is cultured to induce preferential survival of cells of the selected lineage. Those cells that express the selectable marker are then selected for. Progenitors of selected lineage are also described as is the use of the method in assay techniques.

Abstract: The present invention provides a method of enhancing an immune response to apoptotic cells, the method comprising administration of a specific binding member which specifically binds to a microbial antigen. Also provided are pharmaceutical compositions comprising such antibodies and assays to identify specific binding members capable of enhancing an immune response to apoptotic cells. Also described are methods for the treatment of cancer using antibodies which bind to an apoptotic cell intracellular antigen.

Abstract: Animal stem cells are obtained and maintained by culturing cells containing, in the genome, a selectable marker. Differential expression of the selectable marker enables preferential survival and/or division of the desired stem cells compared to the non-stem cells.

Abstract: A method for generating a culture that is purified or enriched in respect of cells of a selected lineage is described in which a selectable marker, which is differentially expressed in cells of the selected lineage compared with its expression in other cells, is introduced into a multipotential cell and the multipotential cell is cultured to induce differentiation of the multipotential cell into a cell of the selected lineage or into a mixture of cells including cells of the selected lineage, or is cultured to induce preferential survival of cells of the selected lineage. Those cells that express the selectable marker are then selected for. Progenitors of selected lineage are also described as is the use of the method in assay techniques.

Abstract: Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer

Abstract: The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl, acyl, cycloalkyl, heterocyclyl, alkenyl, aralkenyl, alkinyl, cycloalkenyl, or X1 and X2 together represent a group R1R2NR4NR1R2 wherein R1 and R2 have the same meaning as before, and R4 represents an optionally substituted divalent, saturated or unsaturated, alkyl chain, an optionally substituted divalent, saturated or unsaturated cycloalkyl or an optionally substituted divalent aryl, or R4 or two or more of R1, R2, R3 and R4 and the respective N atom(s) to which they are linked, represent an optionally substituted heterocyclyl having at least one ring containing said N atom(s); and Y1 and Y2 are the same or different or when cis together represent a divalent moiety Y3, wherein at least one of Y1 and Y2, or Y3, is a substantially labil

Abstract: Provided is a multiple-input multiple-output (MIMO) data transmission method. A transmitter generates a transmission symbol by adding a parity symbol to a predetermined number of data symbols, generates a preprocessed symbol by multiplying the predetermined number of transmission symbols by a preprocessing matrix in units of blocks, selects a transmission antenna associated with a non-zero transmission symbol among preprocessed transmission symbols constituting the preprocessed symbol, and transmits the preprocessed symbol via the selected transmission antenna. A receiver receives a signal transmitted from the transmitter, estimates a preprocessed symbol and a transmission antenna index from the received signal, and restores the transmission symbols using the estimated preprocessed symbol and transmission antenna index.

Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.

Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.

Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.

Abstract: A method for designing a computational device or circuit having one or more desired characteristics, preferably input and/or output characteristics. The method involves using an inner, iterative search that is preferably used within one or more genetic operators. As a first step, one of a population of computational circuits or devices is selected. Once this is done a point in the selected circuit or device is chosen and characterised in terms of the circuit inputs and/or outputs. A parameter or characteristic associated with the selected point is then modified and the point is re-characterised. This is repeated to provide characterisations for a plurality of modified versions of the circuit. Then, the circuit that has characteristics closest to the desired characteristics is identified and added to the population of circuits, and the inner search loop is repeated for another one of the population.

Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.

Abstract: According to one aspect of the present invention there is provided a coating material comprising: a functional coating component; and a fluorescent additive component whose fluorescence is substantially unquenched by the coating component, the fluorescent additive component having a peak fluorescence emission under excitation by visible or infrared light, the wavelength of that peak fluorescence emission being greater than 500 nm and lying outside the principal fluorescence absorption and emission wavelengths of the coating component.

Abstract: A gene trap vector comprises a DNA construct containing an expression unit of an internal ribosome binding site (IRES) coupled to a heterologous gene sequence; this expression unit is used in gene trap protocols to obtain expression of the heterologous gene in the host.

Abstract: Ruthenium (II) compounds of the formula: wherein: R1 is —CO2CH3; R2, R3, R4, R5 and R6 independently represent H, alkyl, cylcoalkyl, —CO2R?, aryl or alkylaryl, which latter two groups are optionally substituted on the aromatic ring; R? represents alkyl, cylcoalkyl, aryl or alkaryl; X is halo, H2O, (R?)(R?)SO, R?CO2? or (R?)(R?)C?O, where R? represents alkyl, cylcoalkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C? is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently R11—CN, where R? represents alkyl or cycloalkyl; or B is halo and A is 4-substitued pyridine; or p is 0, A is NR7R8 and B is NR9R10wherein R7, R8, R9 and R10 independently represent H, or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain; or p is 1, A is NR7 and B is NR9R10, wherein R7, R9 and R10 are as previously defined, and A a

Abstract: Pluripotency determining factors are described which act intracellularly and maintain a pluripotent cell in a pluripotent state in the absence of gp130 activation, which maintain or confer pluripotency of a human stem cell, which maintain or confer pluripotency of a mouse ES cell, and which maintain or confer pluripotency of a stem cell from a non-permissive strain of mice. The factors and vectors encoding or activating the factors are used to maintain and derive pluripotent cells, especially of higher mammals, including humans.